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AbstrACt 
Objective To explore general dental practitioners’ 
(GDPs’) perceptions of, and attitudes towards, the risks 
of medication-related osteonecrosis of the jaw (MRONJ) 
and the current/potential multidisciplinary approach(es) to 
prevention of the condition.
Design Interpretivist methodology using a grounded 
theory approach and constant comparative analysis to 
undertake an iterative series of semistructured interviews. 
Ritchie and Spencer’s framework analysis facilitated the 
identification and prioritisation of salient themes.
setting Primary care general dental practices in the North 
East of England.
Participants 15 GDPs.
results GDPs are aware of the risk of MRONJ with 
commonly implicated medicines; however, they report 
limited collaboration between professional groups in 
person-centred avoidance of complications, which is a 
key requirement of the preventive advice recommended 
in extant literature. Four salient and inter-related themes 
emerged: (1) perception of knowledge; indicating the 
awareness of the risk, limited knowledge of implicated 
medications and experience of managing the condition; 
(2) risk; indicating the importance of accurate medication 
histories, the treatment of low risk patients in primary 
dental care, counselling of poorly informed patients, the 
fear of litigation and perceived low priority of oral health 
in the context of general health and well-being; (3) access 
and isolation; referring to access to general medical 
records, professional isolation and somewhat limited 
and challenging professional collaborative relationships; 
(4) interprofessional working; indicating oral health 
education of other professional groups, collaboration and 
communication, and a focus on preventive care.
Conclusions Patients continue to be at risk of developing 
MRONJ due to limited preventive interventions and 
relatively disparate contexts of multidisciplinary team 
healthcare. Effective collaboration, education and access 
to shared medical records could potentially improve 
patient safety and reduce the potential risk of developing 
MRONJ.
IntrODuCtIOn
Bisphosphonates were first implicated in the 
pathogenesis of medication-related osteone-
crosis of the jaw (MRONJ) in 20031; however, 
other medications such as the antiangiogenic 
drugs, bevacizumab, sunitinib and afliber-
cept, and the receptor activator of nuclear 
factor kappa-beta ligand inhibitor denos-
umab have subsequently also been associated 
strengths and limitations of this study
 ► Although medication-related osteonecrosis of the 
jaw (MRONJ) is not a common finding, affected 
patients experience significant morbidity and man-
agement of this condition warrants further study to 
improve patient care.
 ► This is the first qualitative study that has explored 
the attitudes and perceptions of general dental 
practitioners  (GDPs) towards the multidisciplinary 
approach to preventing MRONJ.
 ► A qualitative method yielded rich data through 
in-depth semistructured interviews with GDPs; 
constant comparative analysis allowed further ex-
ploration and refining of emergent themes.
 ► The study was based around an a priori assump-
tion of limited knowledge among GDPs in relation to 
MRONJ; participants were provided a patient infor-
mation leaflet in advance, therefore exposing partic-
ipants to the concepts before the interview.
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with the condition.2 MRONJ is defined as exposed bone, 
or bone that can be probed through an intraoral or extra-
oral fistula, in the maxillofacial region that has persisted 
for >8 weeks in patients with a history of treatment with 
antiresorptive or antiangiogenic drugs, and where there 
has been no history of radiation therapy to the jaw or no 
obvious metastatic disease to the jaw.3 
MRONJ is a rare complication; the estimated incidence 
in cancer patients treated with antiresorptive or antian-
giogenic drugs is 1% and, in osteoporosis patients treated 
with antiresorptive drugs, is 0.01%–0.1%.2 However, 
MRONJ is difficult to treat and can cause significant 
morbidity to patients; our previous qualitative study of 
patients diagnosed with MRONJ highlighted the signif-
icant quality of life implications, particularly the phys-
ical, psychological and social impacts associated with the 
condition.4
Prescribing rates of drugs associated with MRONJ 
have risen significantly in recent years and are expected 
to rise further. Prescribing of denosumab has increased 
in the UK with an estimated 24.4% rise in National 
Health Service (NHS)expenditure on the drug between 
2015/2016 and 2016/2017.5 The introduction of intra-
venous bisphosphonates in the treatment of early breast 
cancer also approximates to a further 20 000 patients 
being prescribed bisphosphonates annually in the UK.6
Current clinical guidelines recommend that patients 
are to be in a state of optimal dental fitness, relative 
to their condition, specifically with the elimination or 
stabilisation of oral disease before commencement of 
MRONJ-implicated medications, or as soon as possible 
thereafter. A particular focus should be directed towards 
high-risk oncology patients, including a thorough dental 
assessment and the prioritisation of care that reduces 
mucosal trauma or prophylactically reduces the risk of 
subsequent dental extractions.2
A number of studies have described reductions in the 
incidence rates of MRONJ with the execution of appro-
priate screening and preventive dental care.7 8 However, 
a 2015 survey (n=129) identified that >90% of general 
dental practitioners (GDPs) were unaware of medications 
which are associated with MRONJ other than bisphospho-
nates and that 58% of participants were not confident in 
performing an extraction in primary care on a patient 
prescribed oral bisphosphonates.9 The prevention of 
MRONJ should be promoted by the multidisciplinary 
healthcare team with a collaborative approach to the 
education of patients and promotion of high standards of 
oral hygiene and preventive measures.2 10–12
Our previous studies have identified limited aware-
ness of MRONJ among patients, with little promotion of 
appropriate preventive strategies from general medical 
practitioners and pharmacists.4 13 Both of these profes-
sional groups often overlooked the advice related to the 
risk and prevention of MRONJ; the reasons for this were 
multifactorial; however, a lack of awareness of the condi-
tion, complexity of patient medical histories and priori-
tisation of other information, were all potential barriers 
to optimal patient care.4 13 In this study, we have investi-
gated the attitudes and perceptions of GDPs on the risks 
of MRONJ and approaches to its prevention.
Aims
1. To explore the attitudes towards, and perceptions of, 
GDPs on the risks of MRONJ.
2. To explore the attitudes towards, and perceptions of, 
GDPs on the multidisciplinary approach to the preven-
tion of MRONJ.
3. To explore any perceived barriers or enablers to opti-
mising the management of this patient group.
MethOD
Design
The study adopted a grounded theory approach,14 
whereby constant comparative analysis was utilised to 
enrich data through iterative cycles of data collection 
and analysis.15 Individual semistructured interviews were 
undertaken at the participants’ places of work and up 
to 1 hour was designated for each interview conducted. 
An initial topic guide (online supplementary document 
1) was developed by the principal investigator based on 
the extant published literature to date and the findings 
of our previous qualitative study.4 13 The topic guide was 
reviewed and refined by the multidisciplinary research 
team and served as a benchmark for the establishment 
of initial questions. However, flexibility in this process 
and the emergence of particular new themes facilitated 
further exploration during the interview and in subse-
quent data collection with other participants. The inter-
views were audio recorded and transcribed verbatim as an 
integral part of the qualitative analysis methods adopted.
Participants
An invitation letter (online supplementary document 2) 
and participant information sheet (online supplementary 
document 3) were posted to GDPs and disseminated with 
the assistance of the local dental professional network. 
A convenience sample of participants who responded to 
the invitation was implemented initially, with snowball 
sampling adopted to successfully ensure further recruit-
ment to the study.
Analysis
Constant comparative analysis facilitated the enrichment 
of data and further exploration of emerging theoretical 
concepts in subsequent interviews. Ritchie and Spencer’s 
framework analysis16 provided a systematic approach to 
data analysis and allowed the identification and priori-
tisation of salient themes from the data16; themes were 
reviewed by the principal investigator (AS) and the 
research team until definitive concepts became evident.
Patient and public involvement
A patient representative from the University of Sunder-
land Patient, Carer and Public Involvement Group 
was involved in coconstructed discussions around the 
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practical implications of the design and ethical issues 
associated with this study.
results
A total of 15 GDPs participated in this study (table 1). 
In-depth semistructured interviews were carried out 
between May 2018 and September 2018 until theoretical 
emergence of the data was exhausted.
Four salient inter-related themes emerged from the 
data: (1) perceived knowledge; (2) risk; (3) access and 
isolation; (4) interprofessional working.
Perceived knowledge
The concept of MRONJ was introduced in the partici-
pant information sheet provided in advance of the inter-
view; however, all participants reported prior awareness 
of the risk of osteonecrosis of the jaw posed by certain 
medications.
Even though it’s a low risk, as a dentist, maybe just I 
know that it—it’s such a difficult condition to manage 
and can’t really be managed that well. (D1)
All participants were able to identify bisphosphonates 
as being associated with MRONJ; there was limited knowl-
edge of other implicated medications.
That’s the only one (bisphosphonates) that I am real-
ly aware of. There’s probably, maybe, other ones, but 
I really wouldn’t know what they are. (D4)
All participants had at least some (though minimal) 
experience of managing patients with MRONJ; this was 
mostly gained during their undergraduate studies and 
participants had very limited or no exposure to patients 
with MRONJ in their subsequent general practice.
I’ve seen it as an undergraduate, but I have never 
seen it in practice. I think this particular patient that I 
saw was quite disfigured by it and had been attending 
the dental hospital for a long time. (D1)
Most of the participants were aware of guidelines for 
the prevention and management of MRONJ. Although 
all participants practiced in England, the Scottish Dental 
Clinical Effectiveness Programme (SDCEP) Guideline 
was cited as a good source of information2; those partic-
ipants who had qualified most recently described being 
directed to these guidelines during their undergraduate 
study.
The guideline I usually tend to use for everything is 
the Scottish ones, SDCEP . (D3)
risk
Participants described the importance of taking accurate 
medication histories for each patient; a particular focus 
was directed towards certain medications such as antico-
agulants and bisphosphonates.
I’m looking out for any bisphosphonate really, and 
warfarin, any anticoagulants, they are the main ones. 
(D2)
Participants were aware that the risk of MRONJ is small 
for patients who are taking oral bisphosphonates and that 
intravenous formulations carry a higher risk. The risk 
of MRONJ developing following a dental extraction in 
patients prescribed oral medications was deemed to be 
small and this procedure was considered typically suitable 
for general practice. Patients receiving intravenous medi-
cations associated with a cancer diagnosis were perceived 
to be at higher risk and participants reported that they 
would typically refer these patients to secondary care.
The way I view it—if—if they are on IV or if they have 
had IV bisphosphonates recently, then I would see it 
as high risk and I would probably refer to oral sur-
gery. If they are on long-term oral then I am not con-
cerned and would do the extraction. (D10)
All participants reported that they discuss the risk 
with patients prior to carrying out treatment; however, 
participants described the limited awareness of patients 
on the oral risks associated with medications implicated 
in MRONJ. Typically, information regarding this was 
introduced to the patient by the dentist prior to invasive 
procedures and had not been introduced at the point of 
prescribing or dispensing the medication.
The patients don’t really have a clue to be honest, I 
think dentists are aware but I am not sure anyone else 
even knows about it. (D10)
It should come from the person prescribing I sup-
pose, it’s not me that is putting the patient on these 
drugs, but it would be up to me to guide them 
through what’s appropriate for them once they are 
prescribed them. (D6)
Table 1 Participant characteristics
Participant Identifier
No of years’ since 
graduation Gender
1 D1 5–9 Female
2 D2 <5 Male
3 D3 5–9 Female
4 D4 <5 Male
5 D5 >20 Male
6 D6 <5 Female
7 D7 >20 Male
8 D8 >20 Male
9 D9 <5 Male
10 D10 5–9 Male
11 D11 5–9 Female
12 D12 <5 Female
13 D13 >20 Female
14 D14 5–9 Female
15 D15 <5 Male
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Although there are guidelines that inform prevention, 
treatment planning and the management of MRONJ, the 
fear of litigation following an extraction and subsequent 
development of osteonecrosis was an emergent theme 
from the data.
I don’t think it’s a big risk, at least not with orals [oral 
bisphosphonates], but I think it’s a litigation thing re-
ally, protecting yourself and making sure the patient 
is informed, rather than it being a massive risk. (D9)
Oral health was perceived to be low down the list of 
priorities for other healthcare professionals, particularly 
among medical colleagues.
I feel like whenever I have spoken to a GP about any-
thing related to dentistry, they are kind of very much 
of the opinion, ‘that’s your job and not mine, you 
know better so sort it out’. (D14)
A lot of the time they don’t think of oral health as—
as being high up on that—on that priority list. You 
know, they think about everything else, but the teeth 
and gums are an afterthought. (D10)
Access and isolation
Participants described challenges in obtaining accurate 
medication histories from some patients; the relative 
degree of time it takes when dentists are required to 
contact general medical practitioners was seen as a signif-
icant barrier to improving patient care.
I make sure I take medication histories for patients, 
but they don’t always know exactly what they take. It’s 
sometimes hard to be sure the list they give you is 
accurate. (D15)
I think it’s sometimes very difficult to make contact, 
and like, if we try and phone them and they phone 
us, obviously we’re all busy, we never have gaps at the 
same time, it can be really time consuming. (D11)
Access to summary care records (SCRs) was described 
as a key opportunity to save clinical time and ensure that 
dentists were fully aware of the patient’s current medical 
conditions and medication history.
It would be brilliant, if we could just see, even just an 
element of their records, even just what drugs they 
were taking. That’s the main thing for us, it takes so 
long to get the drug history out of a patient. (D13)
Participants described the professional isolation that 
occurs in general dental practice. This indicated isolation 
from other healthcare professionals and potentially from 
other dental colleagues.
I think with a lot of things with dentists really, that 
we are out of the loop, I just don’t seem to have had 
much interaction with any other healthcare profes-
sionals. (D6)
Participants described limited interprofessional rela-
tionships and communication with other healthcare 
professionals in the existing organisational infrastruc-
ture. Typically, communication with general medical 
practitioners would be one way, difficult to initiate, and 
only take place when needing to confirm complex medi-
cation histories.
It’s really just the difficulty getting in touch with them 
and the time that it takes, it’s quite hard to speak to 
the GP. (D3)
I’ve never had a referral from the GP for anything. 
(D2)
Participants reported little collaboration with phar-
macists, and some described a lack of understanding of 
the pharmacist’s role. Communication with pharmacists 
would typically be to discuss issues around prescribing 
errors or with potential drug interactions; some partici-
pants reported communication with pharmacists who run 
anticoagulant therapy monitoring services.
I personally don’t really feel that I’ve got a good 
enough understanding of what an actual pharma-
cist’s job entails. (D2)
The only patients that I have really had any dialogue 
about with pharmacists are those on warfarin. The 
pharmacist runs the anticoagulant monitoring 
service. (D5)
Interprofessional working
A greater focus on oral health education in other health-
care professionals’ training could potentially develop a 
better collaboration between the professions of dentistry 
and general medical practice and facilitate a greater 
understanding of the importance of oral health in rela-
tion to the adverse effects of medication and the links 
between oral health and systemic disease.
I think the importance of oral health could be 
stressed more by other professions and we could 
probably work better together really. You know, some-
times there are medications that have side effects like 
with osteonecrosis and sometimes, there are, there 
are benefits on other condition like diabetes with oral 
health. (D15)
Participants described a willingness to engage with 
other healthcare professionals in order to improve patient 
care. Greater collaboration, clear referral pathways and 
communication with general medical practitioners and 
pharmacists would be well received.
If there was a better multidisciplinary relationship, 
better communication, it would be much better for 
us in terms of delivery of better patient care. (D2)
Yeah definitely. Yeah, I’m more than happy if pharma-
cists could refer appropriate patients, it’s just about 
making sure that the patients know and getting them 
to see me as soon as possible really. (D2)
A greater focus on preventive care and the discussion 
of the oral health implications of medications associated 
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with MRONJ at the point of prescribing would improve 
care for this patient group. This would allow dentists to 
implement preventive strategies before the potential risk 
of MRONJ develops.
If a patient is going to go on to alendronic acid or 
any of the bisphosphonates they should be referred 
to be dentally screened first, because I don’t think 
that happens at all. It could really help to reduce the 
risk if we can do any work and explain things properly 
to the patient first. (D8)
DIsCussIOn
In this research, we undertook semistructured interviews 
to investigate the attitudes and perceptions of GDPs 
on risks of MRONJ and approaches to its prevention. 
Although rare, MRONJ is associated with significant 
morbidity and can develop following common dental 
procedures such as tooth extractions. We therefore 
selected GDPs as a key group of healthcare professionals 
who can play an important role in prevention strategies 
for MRONJ, to explore their knowledge in this area and 
learn from their prior experiences of multidisciplinary 
working. All participants reported being aware of the 
risk of MRONJ; however, it should be noted that this was 
introduced through the patient information leaflet given 
to participants as part of the consent process, therefore 
exposing participants to the concept before the inter-
view. Although participants had minimal experience of 
managing patients with MRONJ, it was apparent that 
GDPs are aware of the risks associated with bisphospho-
nate therapy and the importance of prioritising preven-
tive care in this patient group. Our previous qualitative 
studies of general medical professionals, pharmacists 
and patients found that patients have poor awareness 
of the risk of MRONJ and that preventive strategies are 
rarely implemented at the point of prescribing impli-
cated medicines.4 13 Participants in the current study 
have also reported similar experiences, as they often treat 
patients who are poorly informed about the associated 
risks of bisphosphonate use. All three studies suggest that 
patients are being poorly informed about the need for 
high standards of oral health and that preventive dental 
care is not being recommended. The multidisciplinary 
team appear to be working in relative isolation from one 
another, when prescribing and managing patients who 
have already been prescribed medications that are linked 
with the potential development of MRONJ.
Further education of dentists on specific medications, 
other than bisphosphonates, implicated in the pathogenesis 
of MRONJ is also required. The participants interviewed in 
our study had limited knowledge of other implicated medi-
cines, with most participants only aware of the association 
with bisphosphonate therapy. These findings correspond 
with those of Tanna9 who identified that more than 90% of 
GDPs were unaware of medications other than bisphospho-
nates which are associated with MRONJ.9
Participants were clear in the need to obtain accurate 
medical and medication histories from patients as part 
of routine care. Participants described their current prac-
tices and confidence in treating many patients prescribed 
the implicated medications in the context of primary 
care; however, they would typically find that patients 
would be unaware of the risks associated with them. It is 
clear that the recommendations in current guidelines are 
not always followed and that education of prescribers and 
pharmacists on the risks of MRONJ is required to ensure 
that patients are fully informed at the point of initiating 
pharmacological therapy.
The importance of counselling patients fully on the 
risks before treatment was highlighted by participants 
who also referred to the potential risk of litigation from 
a poorly informed patient or from patients who develop 
MRONJ following a dental procedure. Although not 
reported by all, a fear of litigation was clearly a consid-
eration for some participants. A survey by Tanna9 of 129 
GDPs found that 21% identified a fear of litigation as 
a reason for not performing an extraction in primary 
care.9 Participants in our study were, however, willing to 
perform extractions on lower risk patients prescribed 
oral bisphosphonates in primary care; this follows recom-
mendations in current clinical guidelines, of which most 
participants were aware. A 2014 paper highlighted that 
the legal implications of MRONJ are complex; however, 
legal liability and malpractice claims have been made.17 
The authors identified the need for dentists and other 
healthcare professionals to have an understanding in 
relation to knowledge of MRONJ, provision of informa-
tion to patients, prevention, diagnosis and treatment.17
Participants reported that GDPs are often isolated 
contextually, situationally and geographically from peers 
and other healthcare professionals; this was identified by 
participants as a potential barrier to optimal care of this 
patient group. This is similar to the findings of a previous 
qualitative study which explored the collaborative 
management of patients with diabetes; the researchers 
identified an isolated knowledge base and a perceived 
division between the medical and dental professions to 
negatively impact patient care.18 Professional isolation 
among dentists has also been reported in other studies; 
recent research into the mental health and well-being of 
UK dentists by the British Dental Association identified 
professional isolation as a contributing factor in mental 
illness and burnout among dentists.19
SCRs are an electronic summary of key clinical informa-
tion, such as medicines, allergies and adverse drug reac-
tions that are created from GP medical records. More than 
96% of the population in England currently have an SCR, 
which is accessible from a variety of NHS service providers, 
including hospitals and community pharmacies; however, 
GDPs do not currently have access to SCRs.20 Participants 
reported challenges in taking accurate medication histories 
posed by the existing healthcare infrastructure in which they 
operate, with access to patient’s SCRs described as a poten-
tially useful opportunity to improve care and safeguard 
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patient safety. Sharing medical records with dental prac-
tices could save clinical time for dentists and reduce the 
risk to patients by ensuring that GDPs have the required 
information to make informed decisions about proposed 
dental health interventions. This could potentially benefit 
patients at risk of MRONJ and directly contribute to the 
improvement of oral health-related outcomes and poten-
tially increase the opportunity for the safe(r) management 
of other patient groups.
Mechanisms of reducing both perceived and actual 
professional isolation, improving collaborative care 
and mechanisms of communication between profes-
sions should also be reviewed. The house of care model 
provides a framework for patient centred co-ordinated 
care in the context of diabetes management,21 22 this 
model relies onfour key components: (1) engaged and 
informed individuals, (2) professionals committed to 
partnerships, (3) organisational and supporting processes 
and (4) system wide approaches to commissioning. The 
integration of oral healthcare into the wider healthcare 
system following this model could potentially address the 
issues identified in our research, optimise prevention of 
MRONJ and also address other areas in which oral health 
impacts the overall health and well-being of patients. 
Further research into how this model could be imple-
mented, the development of coordinated services and the 
integration of oral health into primary care settings could 
potentially have significant benefits to patients.
Participants perceived that oral health is low down the 
priority list of other (non-dental) healthcare professionals. 
It is apparent that relationships between GDPs and other 
professional groups are limited and that effective collabora-
tion and communication could significantly improve care 
of this patient group. A focus on the collective education of 
the multidisciplinary team, highlighting the importance of 
preventive dental care and taking opportunities to actively 
reinforce the need for good oral health to patients, could 
be a key mechanism of facilitating and potentially reducing 
patients’ risk of developing MRONJ.
COnClusIOn
Participants identified awareness of the risk of MRONJ, but 
had limited knowledge of implicated medicines other than 
bisphosphonates. GDPs place importance on the establish-
ment of accurate medication histories from patients and 
ensure that patients are informed about the risk of devel-
oping MRONJ if invasive dental treatment is required.
Barriers to optimal patient care include a perception 
that oral health is a low-priority area for other healthcare 
professionals, a feeling of professional isolation, limited 
interprofessional collaboration and a lack of access to 
medical records.
An increased focus on preventive dental care with educa-
tion of other healthcare professionals on the importance 
of oral health, integration of oral health into collaborative 
care models and access to medical records could potentially 
improve patient safety and reduce the risk of the develop-
ment of MRONJ in practice.
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